SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?


To: GREG FINLEY who wrote (188)6/1/1998 12:28:00 PM
From: James Strauss  Respond to of 534
 
Greg:

I like the potential for this company... Their Bioject 2000 needleless immunization system and Glucose Testing system offer very big market potential... The market is beginning to recognize this... The stock is up over 10% today...

Jim



To: GREG FINLEY who wrote (188)6/1/1998 8:18:00 PM
From: Marc Kahn  Read Replies (1) | Respond to of 534
 
Greg,

Given the potential for the GlucoTrax technology, Bioject is seriously undervalued. It seems to be under accumulation by some big players. The action today was overwhelmingly on the ask side of the price spread.

Check out my post # 162 where I talk about Cygnus's fall from favor. I still think that $5.50 per share is a reasonable expectation.

Marc Kahn